Publications
Electroporation of epicardial autonomic ganglia: Safety and efficacy in medium‐term canine models
Pre-Clinical
D Padmanabhan, N Naksuk, AK Killu et al
J Cardiovasc Electrophysiol 2019.
This study was performed using sub-xiphoid access with acute measurements showing that ganglionated plexi ablation produced an extension in the atrial effective refractory period (AERP). Extensive histology evaluations at four month follow-up demonstrated ablation of ganglia structures with sparing of the myocardium. The animals were resistant to AF induction at four months.
Open-chest Pulsed Electric Field Ablation of Cardiac Ganglionated Plexi in Acute Canine Models
Pre-Clinical
M van Zyl, M Khabsa, JA Tri et al
J Innov Cardiac Rhythm Manage 2022.
This open-chest study was performed as full system validation before progressing to first-in-human open-chest clinical trials. It’s utilized AtriAN’s cardiac-customized pulsed field generator and devices designed specifically for open-chest epicardial treatment. Acute extensions in atrial effective refractory period (AERP) were demonstrated as well as evidence of reversible electroporation in myocardial tissue.
Safety and Feasibility of Epicardial Percutaneous Access and Maneuverability With a Novel Ablation Catheter for the Treatment of Atrial Fibrillation in a Porcine Model
Pre-Clinical
P Buszman, K Lukasik, S Deane et al
J Am Coll Cardiol 2021 (Supplement).
This was a first feasibility of epicardial access using the initial prototype of a next generation catheter system designed for sub-xiphoid access and with bipolar ablation capability. Access to the pericardial space was demonstrated with conventional needle technology and the catheter demonstrated promising tracking and navigation performance.